{"id":400698,"date":"2020-12-16T07:03:36","date_gmt":"2020-12-16T12:03:36","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400698"},"modified":"2020-12-16T07:03:36","modified_gmt":"2020-12-16T12:03:36","slug":"ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/","title":{"rendered":"Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Dec.  16, 2020  (GLOBE NEWSWIRE) &#8212; Ovid Therapeutics Inc.\u00a0(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 21, 2020.<\/p>\n<p>The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market\u00ae\u00a0(NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually and all securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and share volume requirements among other criteria. The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology Index<sup>SM<\/sup>\u00a0Fund. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. For more information about the NASDAQ Biotechnology Index visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eb4dDlklEfAPuCQZQN-CVbLUR0Z4GzA2Mlkhm0hskKxPbeI1wVl9cGACdhlMun9Fhj25TAew5dc-Na9sT8fywuuribEUmzgw2IdFWRoUyenSy6_Ni0dr-b4wbSEtHhbKjrjeO0kUEvLbkiFsZAqd39tUD7-JIZ_q1rZqMUtUM6I=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/indexes.nasdaqomx.com\/Index\/Overview\/NBI<\/a>.<\/p>\n<p>\n        <strong>About Ovid Therapeutics<\/strong>\n      <\/p>\n<p>Ovid Therapeutics Inc.\u00a0is a\u00a0New York-based biopharmaceutical company using its BoldMedicine<sup>\u00ae<\/sup>\u00a0approach to develop medicines that transform the lives of patients with rare neurological disorders. The Company is developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited, which is expected to initiate its pivotal clinical trials in 2021 for the potential treatment of rare developmental and epileptic encephalopathies (DEEs). OVID is evaluating the results of the NEPTUNE trial of OV101 (gaboxadol) for the treatment of Angelman syndrome \u00a0and Fragile X syndrome. For more information on Ovid, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nzK1WeoOhzYKLjLtFYYHWVjoeKJAZXDqaKOEs1MIJD__8qhQe90YyYUmG9czRPQ9FfvTeljI4mB4tsA2StHURWzi4WK1obF5NyJVl-zwB89XgRnfcefQKvwyOqNaTm54YYJ-Uz6sugb1jyzbCjw_rnmJ-cQ01JoySzW9AfWHCiHlzdQo-99uFsmFb57ckDYLi4_9iX3tl7p_ybZsfiOGUJFdCr6pmMJv-rGUzdeJWak=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.ovidrx.com<\/u><\/a>.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>\n        <strong>Investors and Media:<\/strong><br \/>\n        <br \/>Ovid Therapeutics Inc.<br \/>Investor Relations &amp; Public Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RXnSFxuc1jq9qyFrnk_tgq5JnNZovuKvCvDUbaLFj8RQhiwHk5W0-Phb2qHsrTU90ox2_KppbypKBcAQCJAGWw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">irpr@ovidrx.com<\/a><\/p>\n<p>OR<\/p>\n<p>\n        <strong>Investors:<\/strong><br \/>\n        <br \/>Argot Partners<br \/>Maeve Conneighton\/Dawn Schottlandt<br \/>212-600-1902<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YrXGNX4N0hi_xLWVpyIPCFg2U5BqG3G3Dizq21I0jJaTO6ropIv-TvSQKwWOCq-q811UvLiVDxUEWmmI-wiy1ta7Dl9Mv_V__YAmB8VzH-4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ovid@argotpartners.com<\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Dan Budwick<br \/>1AB<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7xcXDssjh7yZGcngTGx1yKDXOe15PHkQHzTTWZJTaZsX5DNl8W7xI0YkWg1YNjnx0KUoWYUfAk5t7g9f_fywbQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">dan@1abmedia.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjY0MyMzODgyNjIxIzIwNzAyNjA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/cc7e3ef1-f151-4506-8b48-d76b9db1b75e\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; Ovid Therapeutics Inc.\u00a0(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market\u00ae\u00a0(NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually and all securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400698","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; Ovid Therapeutics Inc.\u00a0(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market\u00ae\u00a0(NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually and all securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and &hellip; Continue reading &quot;Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-16T12:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjY0MyMzODgyNjIxIzIwNzAyNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index\",\"datePublished\":\"2020-12-16T12:03:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\\\/\"},\"wordCount\":312,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjY0MyMzODgyNjIxIzIwNzAyNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\\\/\",\"name\":\"Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjY0MyMzODgyNjIxIzIwNzAyNjA=\",\"datePublished\":\"2020-12-16T12:03:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjY0MyMzODgyNjIxIzIwNzAyNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjY0MyMzODgyNjIxIzIwNzAyNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/","og_locale":"en_US","og_type":"article","og_title":"Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index - Market Newsdesk","og_description":"NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; Ovid Therapeutics Inc.\u00a0(NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI). The addition will become effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market\u00ae\u00a0(NASDAQ\u00ae) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is re-ranked annually and all securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and &hellip; Continue reading \"Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-16T12:03:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjY0MyMzODgyNjIxIzIwNzAyNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index","datePublished":"2020-12-16T12:03:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/"},"wordCount":312,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjY0MyMzODgyNjIxIzIwNzAyNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/","name":"Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjY0MyMzODgyNjIxIzIwNzAyNjA=","datePublished":"2020-12-16T12:03:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjY0MyMzODgyNjIxIzIwNzAyNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjY0MyMzODgyNjIxIzIwNzAyNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ovid-therapeutics-announces-addition-to-the-nasdaq-biotechnology-index\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400698"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400698\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}